Notice of Investigation: Melanoma Predictive and Prognostic Tests
Estimated reading time: 2–4 minutes
The U.S. International Trade Commission (USITC) has announced a new investigation. This investigation is about melanoma predictive and prognostic tests. Castle Biosciences, Inc. from Friendswood, Texas filed a complaint. This was done on July 10, 2026.
The complaint states that there are unfair acts related to importing these tests into the U.S. It involves false and misleading advertising. This may threaten an industry in the U.S. Castle Biosciences wants the Commission to look into this. They also want certain orders issued.
The investigation will see if there is a violation. This falls under subsection (a)(1)(A) of section 337 of the Tariff Act of 1930. The accused products include melanoma predictive and prognostic CP-GEP tests and components.
The named respondents include:
- SkylineDx Holding B.V., based in Rotterdam, Netherlands.
- SkylineDx USA, Inc., located in San Diego, California, USA.
- Qiagen GmbH, from Hilden, Germany.
- QIAGEN LLC, based in Germantown, Maryland, USA.
Responses to the complaint and notice of investigation are needed within 20 days. This is according to the Commission’s Rules of Practice and Procedure. If respondents do not reply in time, they may lose the right to contest.
The Chief Administrative Law Judge will oversee the proceedings. The Commission aims for a clear and fair examination of the issue.
This move shows the USITC’s ongoing duty to maintain fair competition. They are looking to protect U.S. industries from unfair trade practices.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
